Celularity Inc. (CELUW) स्टॉक विश्लेषण

कंपनी का अवलोकन

Celularity Inc. operates as a specialized developer within the regenerative and cellular medicines landscape, dedicated to addressing complex aging-related and degenerative diseases through its proprietary technology. The organization focuses on creating off-the-shelf placental-derived allogeneic cell therapy product candidates, with a specific emphasis on treating diabetic foot ulcers and Crohn's disease. Although the specific sector and industry classifications are not explicitly defined in the available data, the company functions within the broader biotechnology and healthcare ecosystem, utilizing cellular therapies to potentially offer scalable treatments. The enterprise currently employs 123 individuals to advance its research and development initiatives, while its financial footprint is defined by a trailing twelve-month revenue of $40.58M and a market capitalization that is not publicly disclosed. The combination of a single-digit employee count relative to its revenue generation and the absence of a disclosed market cap suggests the company operates with a lean organizational structure typical of early-stage biotech firms, yet the revenue figure indicates it has achieved a level of commercial traction that distinguishes it from pure research entities.

वित्तीय स्वास्थ्य

The company reported a revenue of $40.58M for the trailing twelve months, contrasted sharply by a net income of -$80,647,000 and an EBITDA of -$41,355,000, which collectively reveal a significant divergence between top-line sales and bottom-line profitability. The substantial gap between the $40.58M revenue and the -$80.6M net income highlights a cost structure where operating expenses and costs of goods sold vastly exceed the revenue generated, a common characteristic in capital-intensive pharmaceutical development before regulatory approval or widespread adoption. Despite the negative net income, the company maintains a positive free cash flow of $12.79M, which provides a degree of financial flexibility by indicating that operational cash generation exceeds capital expenditures during this period. Profitability metrics further illustrate the financial strain, with a gross margin of 50.6% suggesting that the cost of producing each unit is less than half the selling price, while an operating margin of -243.2% and a profit margin of -198.7% confirm that overhead costs are currently consuming more than the total revenue. In terms of leverage, the company holds $120,000 in cash against $66.76M in total debt, resulting in a negative price-to-book ratio of -0.01 and an undefined debt-to-equity ratio, which signals a highly leveraged balance sheet reliant on external financing. The current ratio stands at 0.16, indicating that the company's current assets are significantly lower than its current liabilities, suggesting a tight liquidity position that requires careful management of short-term obligations. Return on equity is not calculable due to the accounting structure, while return on assets is -25.0%, reflecting that the company's assets are currently generating negative returns on the capital employed.

मूल्यांकन आकलन

The trailing P/E ratio and forward P/E ratio are both listed as N/A, which is consistent with the company's negative earnings and implies that traditional earnings-based valuation multiples are currently inapplicable for assessing the stock's value trajectory. The price-to-book ratio is recorded at -0.01, indicating that the market capitalizes the company at a value that is mathematically below its book value, a scenario often seen in firms with substantial intangible assets or significant accumulated deficits. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also not available, suggesting that investors must rely on other qualitative factors or non-GAAP metrics to gauge the company's valuation relative to peers. The stock exhibits extreme price compression with a 52-week high and low both recorded at $0.01, meaning the current trading price is effectively at the floor of its annual trading range. With a beta of 0.70, the stock demonstrates lower volatility than the broader market, suggesting that its price movements are less sensitive to general market fluctuations compared to large-cap equities.

Growth & Income

Revenue growth for the year-over-year period is -43.2%, while earnings growth is not applicable due to the negative earnings history, indicating a contraction in top-line sales rather than a growth trajectory. Since the company does not pay a dividend, there is no dividend yield or payout ratio to evaluate, which implies that the firm retains all available earnings to fund its operations and research rather than distributing income to shareholders. The absence of dividend payouts aligns with the company's developmental stage, where reinvesting resources into product candidates for diabetic foot ulcer and Crohn's is prioritized over returning capital to investors. Overall, the growth and income profile is characterized by declining revenue and a complete lack of current profitability or dividend income, reflecting the high-risk, high-potential nature of the regenerative medicine sector.